Calliditas is a commercial stage biopharmaceutical company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. In 2021, Calliditas acquired Genkyotex, specializing company in NOX therapies, French & Swiss based.

Location
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2004
  • Number of employees in Switzerland
    1-9
Key business